RecruitingDepressionAnxietyMethamphetamine Dependence
Creatine for Depressed Male and Female Methamphetamine Users
Eligible age
18–59 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
Sponsor: Montana State University
You may qualify if…
- ✓ Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
- ✓ Current diagnosis of major depressive disorder (primary or substance-induced)
- ✓ Current diagnosis of an anxiety disorder (primary or substance-induced)
- ✓ Current Hamilton Depression Rating scale score \> or = to 16
- ✓ Current Hamilton Anxiety Scale score \> = to 18
- ✓ If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation
You may not qualify if…
- ✕ Persons unable to provide adequate informed consent
- ✕ Persons who are at clinically significant suicidal or homicidal risk
- ✕ Primary substance-related diagnosis other than methamphetamine dependence or abuse
- ✕ Positive pregnancy test (females only)
- ✕ History of renal disease
- ✕ Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
- ✕ History of hypersensitivity reaction to creatine
Where it's recruiting
Montana
Missoula
Source: ClinicalTrials.gov · NCT02568878 · last updated 2015-12-11